Structured evidence table for Resveratrol Metabolic Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Resveratrol Metabolic Health Randomized Trial | Obesity, defined as excessive accumulation of adipose tissue, is strongly associated with metabolic complications, including hypertension, dyslipidemia, and type 2 diabetes [,]. | 1 | Gazda Patrycja (2026) | The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review |
| Resveratrol Metabolic Health Randomized Trial | Chronic low-grade inflammation associated with obesity contributes to metabolic dysfunction through the increased production of pro-inflammatory cytokines and adipocytokines []. | 1 | Gazda Patrycja (2026) | The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review |
| Resveratrol Metabolic Health Randomized Trial | 5 6 7 8 9 10 11 Studies show that obesity significantly increases the risk of chronic diseases, including type 2 diabetes, cardiovascular disease, hypertension, dyslipidemia, hyperuricemia, and insulin resistance [,]. | 1 | Gazda Patrycja (2026) | The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review |
| Resveratrol Metabolic Health Randomized Trial | 1 2 3 4 Metabolic disorders pose a serious challenge to healthcare systems worldwide due to their significant impact on quality of life, requiring a holistic approach in the context of prevention, diagnosis, and treatment. | 1 | Gazda Patrycja (2026) | The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review |
| Resveratrol Metabolic Health Randomized Trial | As a result, no phenotype-defined interventional evidence specific to sarcopenic obesity was identified. | 1 | Russo C (2026) | Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials. |
| Resveratrol Metabolic Health Randomized Trial | Conclusion Despite compelling mechanistic convergence, randomized interventional evidence in strictly defined sarcopenic obesity populations is currently lacking. | 1 | Russo C (2026) | Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials. |
| Resveratrol Metabolic Health Randomized Trial | Background Sarcopenic obesity (SO) is an inflammatory-metabolic condition characterized by the coexistence of excess adiposity and impaired skeletal muscle mass and function. | 1 | Russo C (2026) | Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials. |
| Resveratrol Metabolic Health Randomized Trial | Vitamin D and resveratrol modulate regulatory pathways implicated in SO pathophysiology, including NF-κB signaling, PGC-1α, mitochondrial regulation, and redox balance. | 1 | Russo C (2026) | Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials. |
Source documents